Clark Wesley 4

What Happened

• Clark Wesley, a director of ImmunityBio, Inc. (IBRX), received a grant of 65,600 shares on 2026-06-09. The filing records the award as acquired at $0.00 (derivative award/compensation), so no cash was paid. The grant is recorded as an award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Filing date: 2026-06-10 (Form 4 filed within the normal two-business-day window).
• Number of shares awarded: 65,600; Reported price: $0.00 (award/compensation).
• Shares owned after transaction: Not specified in the filing.
• Vesting/conditions: Per footnote, 100% of the shares vest on the earlier of June 9, 2027 or the day immediately preceding the next annual meeting of stockholders, provided Wesley remains a Service Provider under the 2025 Equity Incentive Plan.
• Remarks: Filing includes Exhibit 24 — Power of Attorney.
• Filing timeliness: Not late (filed promptly).

Context

• This is a time‑based equity award (derivative/compensation) subject to a one-year-ish cliff vesting date; it is not an open‑market purchase or a sale. Such grants are common for director compensation and do not by themselves indicate buying or selling sentiment.